CD69 and neoplasm: (F) Quantification of CD69 and CD103 co-expression revealed CD69- CD103- in PBMC and CD69+ CD103- and CD69+ CD103+ in tumor-periphery as the dominant phenotypes (Figure 6—source data 2).